Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 10—October 2021
Research

Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities, Spain

Susana MongeComments to Author , Carmen Olmedo, Belén Alejos, María Fé Lapeña, María José Sierra1, Aurora Limia1, and COVID-19 Registries Study Group2
Author affiliation: Ministry of Health, Madrid, Spain

Main Article

Table 2

Standardized risk, risk ratio, vaccine effectiveness, and risk difference in residents of long-term care facilities with evidence of previous severe acute respiratory syndrome coronavirus 2 infection, by time since first vaccinated, Spain, December 27, 2020–March 10, 2021*

Time since vaccination
Events/persons at risk

Standardized risk† (95% CI)
RR 
(95% CI)
VE 
(95% CI)
RD 
(95% CI)
Reference period
Study period
Unexposed
Exposed
Effects in the vaccinated
Full period 412/37,736 519/65,898 1.78
(1.58–1.96)
1.13
(1.02–1.23)
0.64
(0.54–0.72)
36.3
(27.9–45.5)
−0.64
(−0.86 to −0.44)
0–14 d 100/37,736 245/65,898 2.64
(2.22–3.03)
2.39
(2.13–2.63)
0.9
(0.73–1.07)
9.6
(−6.9 to 26.8)
−0.25
(−0.72–0.23)
15–21 d 72/37,440 104/64,988 2.58
(2.26–2.89)
1.92
(1.74–2.09)
0.74
(0.63–0.85)
25.5
(15.1–36.6)
−0.66
(−1.00 to −0.32)
22–28 d 77/36,840 55/63,236 2.2
(1.95–2.44)
1.44
(1.29–1.58)
0.65
(0.56–0.74)
34.6
(25.7–44.1)
−0.76
(−1.03 to −0.5)
>29 d
163/36,288
115/60,176

1.31
(1.11–1.52)
0.57
(0.46–0.67)
0.43
(0.32–0.53)
56.8
(47.1–67.7)
−0.75
(−0.98 to −0.53)
Indirect effects in the unvaccinated
Full period 5/403 9/862 1.32
(0.12–2.55)
1.89
(0.3–3.34)
NE NE NE
0–14 d 4/403 4/862 6.39
(0.64–12.47)
3.39
(0.63–6.05)
NE NE NE
15–21 d 1/394 2/842 0.76
(−0.63 to 2.08)
2.95
(0.97–5.19)
NE NE NE
22–28 d 0/386 1/827 0.16
(−0.4 to 0.6)
2.21
(0.72–3.95)
NE NE NE
>29 d 0/381 2/778 0.01
(−0.04 to 0.04)
1.2
(−0.97 to 3.12)
NE NE NE

*Time since first vaccinated was a proxy of number of vaccine doses and days since last dose. NE, not estimated because of insufficient number of events; RD, risk difference; RR, risk ratio; VE, vaccine effectiveness. †Per 10,000 population per day. ‡Full vaccination.

Main Article

1These senior authors contributed equally to this article.

2Group members are listed at the end of this article.

Page created: July 20, 2021
Page updated: September 19, 2021
Page reviewed: September 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external